

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ABN: 641288155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Perry
Date of last notice	9 September 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	22 December 2021 (United States) / 23 December 2021 (Australia)

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>634,602 CHESSE Depository Interests ("CDIs") in the Company quoted on ASX (representing beneficial ownership of 126,920 shares of common stock in the Company)</p> <p>63,211 shares of common stock in the Company quoted on the NASDAQ Stock Market LLC ("Shares")</p> <p>Dr Perry also held the following convertible securities in AVITA Medical Pty Limited ACN 058 466 523 ("Avita Australia"), being a wholly owned subsidiary of the Company, prior to the change:</p> <ul style="list-style-type: none"> • 15,000,000 unquoted options in Avita Australia (consolidation equivalent = 150,000 unquoted options in the Company) • 7,126,049 unquoted restricted stock units ("RSUs") in Avita Australia (consolidation equivalent = 71,260 unquoted RSUs in the Company) <p>The convertible securities held in Avita Australia entitle Dr Perry, upon vesting of their conversion rights, to be issued shares in the Company (which may be represented by CDIs) rather than ordinary shares in Avita Australia on a consolidation ratio of 100:1 as set out in the Company's pre-quotations disclosure released to the market on 24 June 2020.</p>
<p>Class</p>	<p>a) Unquoted RSUs in the Company to acquire shares of common stock of the Company (which may be represented by CDIs)</p> <p>b) Unquoted options in the Company to acquire shares of common stock of the Company (which may be represented by CDIs)</p> <p>c) Shares</p>
<p>Number acquired</p>	<p>a) 95,280 unquoted RSUs b) 55,200 unquoted options</p>
<p>Number disposed</p>	<p>6,267 Shares</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Acquisition of 95,280 unquoted RSUs and 55,200 unquoted options - nil consideration (issued in accordance with shareholder approval at the 2021 annual general meeting).</p> <p>Transfer of 6,267 Shares - no consideration as transferred to Dr Perry's former wife as part of a marital separation agreement.</p>
<p>No. of securities held after change</p>	<p>634,602 CDIs in the Company quoted on ASX (representing beneficial ownership of 126,920 shares of common stock in the Company)</p> <p>56,944 Shares</p> <p>95,280 unquoted RSUs in the Company</p> <p>55,200 unquoted options in the Company</p> <p>Dr Perry holds the following convertible securities in Avita Australia, being a wholly owned subsidiary of the Company:</p> <ul style="list-style-type: none"> • 15,000,000 unquoted options in Avita Australia (consolidation equivalent = 150,000 unquoted options in the Company) • 7,126,049 unquoted RSUs in Avita Australia (consolidation equivalent = 71,260 unquoted RSUs in the Company) <p>The convertible securities held in Avita Australia entitle Dr Perry, upon vesting of their conversion rights, to be issued shares in the Company (which may be represented by CDIs) rather than ordinary shares in Avita Australia on a consolidation ratio of 100:1 as set out in the Company's pre-quotations disclosure released to the market on 24 June 2020.</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Acquisition of 95,280 unquoted RSUs and 55,200 unquoted options - off market (issued in accordance with shareholder approval at the 2021 annual general meeting)</p> <p>Transfer of 6,267 Shares due to the transfer of Shares to Dr Perry's former wife in accordance with a marital separation agreement</p>
--	---

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A
Interest acquired	N/A
Interest disposed	N/A
<p>Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation</p>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.